产品: CD31 抗体
货号: AF6191
描述: Rabbit polyclonal antibody to CD31
应用: WB IHC IF/ICC
文献验证: WB, IHC, IF/ICC
反应: Human, Rat
预测: Mouse, Pig, Bovine, Horse, Sheep, Rabbit, Dog
蛋白ID: P16284
RRID: AB_2835074

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1100 1250 现货
 100ul RMB¥ 2100 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Rat
克隆:
Polyclonal
特异性:
CD31 Antibody detects endogenous levels of total CD31.
RRID:
AB_2835074
引用格式: Affinity Biosciences Cat# AF6191, RRID:AB_2835074.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin.
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl and glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Adhesion molecule; CD31; CD31 antigen; CD31 EndoCAM; EndoCAM; FLJ34100; FLJ58394; GPIIA; GPIIA'; PECA1; PECA1_HUMAN; Pecam 1; PECAM 1 CD31 EndoCAM; PECAM; PECAM-1; Pecam1; Platelet and endothelial cell adhesion molecule 1; Platelet endothelial cell adhesion molecule; Platelet/endothelial cell adhesion molecule 1;

抗原和靶标

免疫原:

A synthesized peptide derived from human CD31, corresponding to a region within C-terminal amino acids.

基因/基因ID:
描述:
PECAM-1 is a cell adhesion molecule expressed on platelets and at endothelial cell intercellular junctions.

研究领域

· Environmental Information Processing > Signaling molecules and interaction > Cell adhesion molecules (CAMs).   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

文献引用

1). Nanoscale-Engineered Silk Hydrogel for Hierarchical Delivery of Intrinsic Physical-Chemical-Biological Cues to Enhance in Situ Biomineralization and Endogenous Bone Regeneration. ADVANCED FUNCTIONAL MATERIALS, 2026 [IF=19.0]

2). A biomimetic piezoelectric scaffold with sustained Mg2+ release promotes neurogenic and angiogenic differentiation for enhanced bone regeneration. Bioactive materials, 2022 (PubMed: 37056250) [IF=18.9]

Application: IF/ICC    Species: Rat    Sample: bone tissue

Fig. 8. Histological, immunohistological, and immunofluorescence staining for the evaluation of bone regeneration. (A) H&E staining and Masson's trichrome staining for sections collected at 8 W post-operation. (B) Immunohistochemical staining of TRAP and OCN expression at 8 W post-operation. (C) Immunofluorescence staining of CD31 (red), CGRP (green), and DAPI (blue) expression at 4 W and 8 W post-operation.

3). Microtubes with gradient decellularized porcine sciatic nerve matrix from microfluidics for sciatic nerve regeneration. Bioactive materials, 2022 (PubMed: 36185737) [IF=18.9]

4). Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension. ACS Nano, 2023 (PubMed: 37071566) [IF=15.8]

5). Sea Cucumber-Inspired Microneedle Nerve Guidance Conduit for Synergistically Inhibiting Muscle Atrophy and Promoting Nerve Regeneration. ACS nano, 2024 (PubMed: 38776414) [IF=15.8]

6). Turmeric-Derived Nanoparticles Functionalized Aerogel Regulates Multicellular Networks to Promote Diabetic Wound Healing. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024 (PubMed: 38441389) [IF=15.1]

Application: IHC    Species: Mouse    Sample:

Figure 7 In vivo wound-healing effect of TAG. A) Flowchart of experimental procedures. B) Representative photographs of diabetic wounds treated with different formulations on days 1, 4, 7, 10, and 13, respectively. C) Wound contractions of mice treated with PBS, AG, TDNPs, or TAG (n ≥ 7). D) Schematic images of diabetic wound contraction in mice within 13 days of treatment with different formulations. E) H&E and Masson's trichrome staining of the wound tissues obtained from diabetic mice with varied dressings on days 7 and 14, respectively (n = 3). F) Representative DHE staining images of diabetic wounds in each group. G) Statistical data of DHE fluorescence intensity at the wound bed on day 7 (n = 3). H) Representative images of Ki67, CD31, and COL1A1 expressions in different groups of tissues. I) Statistical data of Ki67+ cells, CD31+ area, and COL1A1+ area in tissues obtained from different groups (n = 3). Data are presented as mean ± SD. Statistical significance was based on one-way ANOVA with post-hoc test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. TDNPs, turmeric-derived nanoparticles; TAG, TDNPs-loaded aerogel (TDNPs@AG); PBS, phosphate buffer saline; AG, aerogel; DHE, dihydroethidium; H&E, hematoxylin and eosin.

7). Hypoxia-injured pulmonary vascular targeting and microenvironment-responsive nanoparticle to treat hypoxic pulmonary hypertension. JOURNAL OF NANOBIOTECHNOLOGY, 2026 [IF=15.0]

8). METTL3-dependent m6A modification of SNAP29 induces "autophagy-mitochondrial crisis" in the ischemic microenvironment after soft tissue transplantation. Autophagy, 2025 (PubMed: 40340690) [IF=14.6]

9). Inhibition of PLA2G4E/cPLA2 promotes survival of random skin flaps by alleviating Lysosomal membrane permeabilization-Induced necroptosis. Autophagy, 2022 (PubMed: 34872436) [IF=14.6]

Application: IF/ICC    Species: Mouse    Sample:

Figure 5. Activated PLA2G4E hindered the survival of random-pattern skin flaps. (A) Photograph of random-pattern skin flaps on mice treated with saline, AAV-scramble-I or AAV-Pla2g4e shRNA at different times (0, 1, 3 and 7 days after surgery). (B) Comparison of the survival area among the three groups on postoperative day 7. Data are expressed as the means ± SEM (n = 6). (C) LDBF of random-pattern skin flaps on mice at 1 and 7 days after surgery in each group. (D) Comparison of signal intensity of blood flow in random-pattern skin flaps among the three groups on postoperative day 7. Data are expressed as the means ± SEM (n = 6). (E) Immunofluorescence staining of PECAM1 and ACTA2 in the skin from area II in each group on postoperative day 7. Scale bars: 100 μm. (F) Comparison of the density of PECAM1-ACTA2-positive blood vessels among the three groups. Data are expressed as the means ± SEM (n = 6). (G) F-CHP staining for the detection of damaged collagen in the skin from area II in each group on postoperative day 7. Scale bars: 100 μm. (H) Comparison of the integrated intensity of F-CHP among the three groups. Data are expressed as the means ± SEM (n = 6). Significance: *p < 0.05.

10). Delivery of therapeutic miRNAs using nanoscale zeolitic imidazolate framework for accelerating vascularized bone regeneration. Chemical Engineering Journal, 2022 [IF=13.3]

加载更多

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.